{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:51:33Z","timestamp":1788994293307,"version":"build-2803163510"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T00:00:00Z","timestamp":1519257600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Novartis Italia","award":["medical writing assistance was funded by Novartis, Italy"],"award-info":[{"award-number":["medical writing assistance was funded by Novartis, Italy"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00277-018-3258-0","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T18:15:55Z","timestamp":1519409755000},"page":"745-754","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment"],"prefix":"10.1007","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1163-6162","authenticated-orcid":false,"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigiana","family":"Luciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Benevolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Bonifacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Caocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Castagnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe A.","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Landi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,22]]},"reference":[{"key":"3258_CR1","doi-asserted-by":"publisher","unstructured":"Kowal P, Dowd JE (2001) Definition of an older person. Proposed working definition of an older person in Africa for the MDS project. World Health Organization, Geneva. https:\/\/doi.org\/10.13140\/2.1.5188.9286","DOI":"10.13140\/2.1.5188.9286"},{"issue":"17","key":"3258_CR2","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1200\/JCO.2008.20.8983","volume":"27","author":"BD Smith","year":"2009","unstructured":"Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA (2009) Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 27(17):2758\u20132765. https:\/\/doi.org\/10.1200\/JCO.2008.20.8983","journal-title":"J Clin Oncol"},{"issue":"3","key":"3258_CR3","doi-asserted-by":"publisher","first-page":"e90299","DOI":"10.1371\/journal.pone.0090299","volume":"9","author":"GL Price","year":"2014","unstructured":"Price GL, Davis KL, Karve S, Pohl G, Walgren RA (2014) Survival pattern in United States (US) and medicare enrollees with non-CML myeloproliferative neoplasms (MPN). PLoS One 9(3):e90299. https:\/\/doi.org\/10.1371\/journal.pone.0090299","journal-title":"PLoS One"},{"issue":"3","key":"3258_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.beha.2009.07.007","volume":"22","author":"M Rohrbacher","year":"2009","unstructured":"Rohrbacher M, Hasford J (2009) Epidemiology of chronic myeloid leukemia (CML). Best Pract Res Clin Haematol 22(3):295\u2013302. https:\/\/doi.org\/10.1016\/j.beha.2009.07.007","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"3258_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12875-015-0241-x","volume":"16","author":"L Deckx","year":"2015","unstructured":"Deckx L, van den Akker M, Daniels L, De Jonge ET, Bulens P, Tjan-Heijnen VC, van Abbema DL, Buntinx F (2015) Geriatric screening tools are of limited value to predict decline in functional status and quality of life: results of a cohort study. BMC Fam Pract 16(1):30. https:\/\/doi.org\/10.1186\/s12875-015-0241-x","journal-title":"BMC Fam Pract"},{"issue":"3","key":"3258_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.amjmed.2003.09.031","volume":"116","author":"ME Tinetti","year":"2004","unstructured":"Tinetti ME, Fried T (2004) The end of the disease era. Am J Med 116(3):179\u2013185. https:\/\/doi.org\/10.1016\/j.amjmed.2003.09.031","journal-title":"Am J Med"},{"issue":"12","key":"3258_CR7","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1634\/theoncologist.2014-0237","volume":"19","author":"N Ommundsen","year":"2014","unstructured":"Ommundsen N, Wyller TB, Nesbakken A, Jordhoy MS, Bakka A, Skovlund E, Rostoft S (2014) Frailty is an independent predictor of survival in older patients with colorectal cancer. Oncologist 19(12):1268\u20131275. https:\/\/doi.org\/10.1634\/theoncologist.2014-0237","journal-title":"Oncologist"},{"issue":"13","key":"3258_CR8","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1200\/JCO.2015.63.5839","volume":"34","author":"R Corre","year":"2016","unstructured":"Corre R, Greillier L, Le Caer H, Audigier-Valette C, Baize N, Berard H, Falchero L, Monnet I, Dansin E, Vergnenegre A, Marcq M, Decroisette C, Auliac JB, Bota S, Lamy R, Massuti B, Dujon C, Perol M, Daures JP, Descourt R, Lena H, Plassot C, Chouaid C (2016) Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study. J Clin Oncol 34(13):1476\u20131483. https:\/\/doi.org\/10.1200\/JCO.2015.63.5839","journal-title":"J Clin Oncol"},{"issue":"21","key":"3258_CR9","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1182\/blood-2012-12-471680","volume":"121","author":"HD Klepin","year":"2013","unstructured":"Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, Ellis LR, Powell BL (2013) Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood 121(21):4287\u20134294. https:\/\/doi.org\/10.1182\/blood-2012-12-471680","journal-title":"Blood"},{"issue":"1","key":"3258_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.critrevonc.2012.01.001","volume":"84","author":"M Breccia","year":"2012","unstructured":"Breccia M, Tiribelli M, Alimena G (2012) Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data. Crit Rev Oncol Hematol 84(1):93\u2013100. https:\/\/doi.org\/10.1016\/j.critrevonc.2012.01.001","journal-title":"Crit Rev Oncol Hematol"},{"key":"3258_CR11","volume-title":"Glivec: EPAR\u2014product information","author":"European Medicines Agency","year":"2009","unstructured":"European Medicines Agency (2009) Glivec: EPAR\u2014product information. European Medicines Agency, London"},{"key":"3258_CR12","volume-title":"Jakavi: EPAR\u2014product information","author":"European Medicines Agency","year":"2012","unstructured":"European Medicines Agency (2012) Jakavi: EPAR\u2014product information. European Medicines Agency, London"},{"issue":"7","key":"3258_CR13","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2174\/15680096113139990090","volume":"13","author":"D Russo","year":"2013","unstructured":"Russo D, Malagola M, Skert C, Fili C, Bergonzi C, Cancelli V, Cattina F (2013) Treatment of chronic myeloid leukemia elderly patients in the tyrosine kinase inhibitor era. Curr Cancer Drug Targets 13(7):755\u2013767. https:\/\/doi.org\/10.2174\/15680096113139990090","journal-title":"Curr Cancer Drug Targets"},{"key":"3258_CR14","doi-asserted-by":"publisher","first-page":"e337","DOI":"10.14694\/EDBK_158639","volume":"35","author":"GA Abel","year":"2016","unstructured":"Abel GA, Buckstein R (2016) Integrating frailty, comorbidity, and quality of life in the management of myelodysplastic syndromes. Am Soc Clin Oncol Educ Book 35:e337\u2013e344. https:\/\/doi.org\/10.14694\/EDBK_158639","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"9836","key":"3258_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0140-6736(12)60240-2","volume":"380","author":"K Barnett","year":"2012","unstructured":"Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B (2012) Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 380(9836):37\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(12)60240-2","journal-title":"Lancet"},{"issue":"6","key":"3258_CR16","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1001\/jama.294.6.716","volume":"294","author":"CM Boyd","year":"2005","unstructured":"Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW (2005) Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 294(6):716\u2013724. https:\/\/doi.org\/10.1001\/jama.294.6.716","journal-title":"JAMA"},{"issue":"3","key":"3258_CR17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.critrevonc.2005.06.003","volume":"55","author":"M Extermann","year":"2005","unstructured":"Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz JP, Lichtman S, Mor V, Monfardini S, Repetto L, Sorbye L, Topinkova E (2005) Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55(3):241\u2013252. https:\/\/doi.org\/10.1016\/j.critrevonc.2005.06.003","journal-title":"Crit Rev Oncol Hematol"},{"key":"3258_CR18","doi-asserted-by":"publisher","first-page":"e2010029","DOI":"10.4084\/mjhid.2010.029","volume":"2","author":"L Balducci","year":"2010","unstructured":"Balducci L (2010) Treatment of cancer in the older aged person. Mediterr J Hematol Infect Dis 2:e2010029","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"12","key":"3258_CR19","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1200\/JCO.2009.25.9978","volume":"28","author":"A Luciani","year":"2010","unstructured":"Luciani A, Ascione G, Bertuzzi C, Marussi D, Codeca C, Di Maria G, Caldiera SE, Floriani I, Zonato S, Ferrari D, Foa P (2010) Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13. J Clin Oncol 28(12):2046\u20132050. https:\/\/doi.org\/10.1200\/JCO.2009.25.9978","journal-title":"J Clin Oncol"},{"issue":"6","key":"3258_CR20","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ctrv.2009.04.005","volume":"35","author":"A Brunello","year":"2009","unstructured":"Brunello A, Sandri R, Extermann M (2009) Multidimensional geriatric evaluation for older cancer patients as a clinical and research tool. Cancer Treat Rev 35(6):487\u2013492. https:\/\/doi.org\/10.1016\/j.ctrv.2009.04.005","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"3258_CR21","doi-asserted-by":"publisher","first-page":"e437","DOI":"10.1016\/S1470-2045(12)70259-0","volume":"13","author":"ME Hamaker","year":"2012","unstructured":"Hamaker ME, Jonker JM, de Rooij SE, Vos AG, Smorenburg CH, van Munster BC (2012) Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol 13(10):e437\u2013e444. https:\/\/doi.org\/10.1016\/S1470-2045(12)70259-0","journal-title":"Lancet Oncol"},{"issue":"3","key":"3258_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.cger.2015.04.005","volume":"31","author":"F Landi","year":"2015","unstructured":"Landi F, Calvani R, Cesari M, Tosato M, Martone AM, Bernabei R, Onder G, Marzetti E (2015) Sarcopenia as the biological substrate of physical frailty. Clin Geriatr Med 31(3):367\u2013374. https:\/\/doi.org\/10.1016\/j.cger.2015.04.005","journal-title":"Clin Geriatr Med"},{"key":"3258_CR23","first-page":"29","volume":"13","author":"E Marzetti","year":"2015","unstructured":"Marzetti E, Calvani R, Cesari M, Tosato M, Cherubini A, Di Bari M, Pahor M, Savera G, Collamati A, D'Angelo E, Bernabei R, Landi F (2015) Operationalization of the physical frailty & sarcopenia syndrome: rationale and clinical implementation. Transl Med UniSa 13:29\u201332","journal-title":"Transl Med UniSa"},{"key":"3258_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2016.07.021","volume":"35","author":"M Cesari","year":"2016","unstructured":"Cesari M, Nobili A, Vitale G (2016) Frailty and sarcopenia: from theory to clinical implementation and public health relevance. Eur J Intern Med 35:1\u20139. https:\/\/doi.org\/10.1016\/j.ejim.2016.07.021","journal-title":"Eur J Intern Med"},{"issue":"6","key":"3258_CR25","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jamda.2013.03.022","volume":"14","author":"JE Morley","year":"2013","unstructured":"Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, Cesari M, Chumlea WC, Doehner W, Evans J, Fried LP, Guralnik JM, Katz PR, Malmstrom TK, McCarter RJ, Gutierrez Robledo LM, Rockwood K, von Haehling S, Vandewoude MF, Walston J (2013) Frailty consensus: a call to action. J Am Med Dir Assoc 14(6):392\u2013397. https:\/\/doi.org\/10.1016\/j.jamda.2013.03.022","journal-title":"J Am Med Dir Assoc"},{"issue":"6","key":"3258_CR26","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/annonc\/mdu540","volume":"26","author":"C Handforth","year":"2015","unstructured":"Handforth C, Clegg A, Young C, Simpkins S, Seymour MT, Selby PJ, Young J (2015) The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol 26(6):1091\u20131101. https:\/\/doi.org\/10.1093\/annonc\/mdu540","journal-title":"Ann Oncol"},{"issue":"2","key":"3258_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ctrv.2014.12.010","volume":"41","author":"MT Puts","year":"2015","unstructured":"Puts MT, Tapscott B, Fitch M, Howell D, Monette J, Wan-Chow-Wah D, Krzyzanowska M, Leighl NB, Springall E, Alibhai SM (2015) A systematic review of factors influencing older adults\u2019 decision to accept or decline cancer treatment. Cancer Treat Rev 41(2):197\u2013215. https:\/\/doi.org\/10.1016\/j.ctrv.2014.12.010","journal-title":"Cancer Treat Rev"},{"issue":"13","key":"3258_CR28","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, Offidani M, McCarthy P, Evangelista A, Lonial S, Zweegman S, Musto P, Terpos E, Belch A, Hajek R, Ludwig H, Stewart AK, Moreau P, Anderson K, Einsele H, Durie BG, Dimopoulos MA, Landgren O, San Miguel JF, Richardson P, Sonneveld P, Rajkumar SV (2015) Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 125(13):2068\u20132074. https:\/\/doi.org\/10.1182\/blood-2014-12-615187","journal-title":"Blood"},{"issue":"1","key":"3258_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/bjh.14033","volume":"174","author":"R Buckstein","year":"2016","unstructured":"Buckstein R, Wells RA, Zhu N, Leitch HA, Nevill TJ, Yee KW, Leber B, Sabloff M, St Hilaire E, Kumar R, Geddes M, Shamy A, Storring J, Kew A, Elemary M, Levitt M, Lenis M, Mamedov A, Zhang L, Rockwood K, Alibhai SM (2016) Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study. Br J Haematol 174(1):88\u2013101. https:\/\/doi.org\/10.1111\/bjh.14033","journal-title":"Br J Haematol"},{"issue":"3","key":"3258_CR30","doi-asserted-by":"publisher","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","volume":"56","author":"LP Fried","year":"2001","unstructured":"Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56(3):M146\u2013M156. https:\/\/doi.org\/10.1093\/gerona\/56.3.M146","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"1","key":"3258_CR31","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/gerona\/gls119","volume":"68","author":"L Rodriguez-Manas","year":"2013","unstructured":"Rodriguez-Manas L, Feart C, Mann G, Vina J, Chatterji S, Chodzko-Zajko W, Gonzalez-Colaco Harmand M, Bergman H, Carcaillon L, Nicholson C, Scuteri A, Sinclair A, Pelaez M, Van der Cammen T, Beland F, Bickenbach J, Delamarche P, Ferrucci L, Fried LP, Gutierrez-Robledo LM, Rockwood K, Rodriguez Artalejo F, Serviddio G, Vega E, Fod-Cc group (2013) Searching for an operational definition of frailty: a Delphi method based consensus statement: the frailty operative definition-consensus conference project. J Gerontol A Biol Sci Med Sci 68(1):62\u201367. https:\/\/doi.org\/10.1093\/gerona\/gls119","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"7","key":"3258_CR32","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s12603-012-0084-2","volume":"16","author":"JE Morley","year":"2012","unstructured":"Morley JE, Malmstrom TK, Miller DK (2012) A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J Nutr Health Aging 16(7):601\u2013608. https:\/\/doi.org\/10.1007\/s12603-012-0084-2","journal-title":"J Nutr Health Aging"},{"issue":"5","key":"3258_CR33","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1503\/cmaj.050051","volume":"173","author":"K Rockwood","year":"2005","unstructured":"Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, Mitnitski A (2005) A global clinical measure of fitness and frailty in elderly people. Can Med Ass J 173(5):489\u2013495. https:\/\/doi.org\/10.1503\/cmaj.050051","journal-title":"Can Med Ass J"},{"issue":"8","key":"3258_CR34","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s12603-012-0391-7","volume":"16","author":"J Subra","year":"2012","unstructured":"Subra J, Gillette-Guyonnet S, Cesari M, Oustric S, Vellas B (2012) The integration of frailty into clinical practice: preliminary results from the Gerontopole. J Nutr Health Aging 16(8):714\u2013720. https:\/\/doi.org\/10.1007\/s12603-012-0391-7","journal-title":"J Nutr Health Aging"},{"issue":"12","key":"3258_CR35","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1111\/j.1532-5415.2008.02008.x","volume":"56","author":"MD Rothman","year":"2008","unstructured":"Rothman MD, Leo-Summers L, Gill TM (2008) Prognostic significance of potential frailty criteria. J Am Geriatr Soc 56(12):2211\u20132216. https:\/\/doi.org\/10.1111\/j.1532-5415.2008.02008.x","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"3258_CR36","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1111\/j.1532-5415.2006.00914.x","volume":"54","author":"JL Purser","year":"2006","unstructured":"Purser JL, Kuchibhatla MN, Fillenbaum GG, Harding T, Peterson ED, Alexander KP (2006) Identifying frailty in hospitalized older adults with significant coronary artery disease. J Am Geriatr Soc 54(11):1674\u20131681. https:\/\/doi.org\/10.1111\/j.1532-5415.2006.00914.x","journal-title":"J Am Geriatr Soc"},{"issue":"sep09 1","key":"3258_CR37","doi-asserted-by":"publisher","first-page":"c4467","DOI":"10.1136\/bmj.c4467","volume":"341","author":"R Cooper","year":"2010","unstructured":"Cooper R, Kuh D, Hardy R (2010) Objectively measured physical capability levels and mortality: systematic review and meta-analysis. Br Med J 341(sep09 1):c4467. https:\/\/doi.org\/10.1136\/bmj.c4467","journal-title":"Br Med J"},{"issue":"15","key":"3258_CR38","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1001\/archinternmed.2012.2555","volume":"172","author":"MC Odden","year":"2012","unstructured":"Odden MC, Peralta CA, Haan MN, Covinsky KE (2012) Rethinking the association of high blood pressure with mortality in elderly adults: the impact of frailty. Arch Intern Med 172(15):1162\u20131168. https:\/\/doi.org\/10.1001\/archinternmed.2012.2555","journal-title":"Arch Intern Med"},{"issue":"1","key":"3258_CR39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jama.2010.1923","volume":"305","author":"S Studenski","year":"2011","unstructured":"Studenski S, Perera S, Patel K, Rosano C, Faulkner K, Inzitari M, Brach J, Chandler J, Cawthon P, Connor EB, Nevitt M, Visser M, Kritchevsky S, Badinelli S, Harris T, Newman AB, Cauley J, Ferrucci L, Guralnik J (2011) Gait speed and survival in older adults. JAMA 305(1):50\u201358. https:\/\/doi.org\/10.1001\/jama.2010.1923","journal-title":"JAMA"},{"issue":"10","key":"3258_CR40","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s12603-009-0246-z","volume":"13","author":"G Abellan van Kan","year":"2009","unstructured":"Abellan van Kan G, Rolland Y, Andrieu S, Bauer J, Beauchet O, Bonnefoy M, Cesari M, Donini LM, Gillette Guyonnet S, Inzitari M, Nourhashemi F, Onder G, Ritz P, Salva A, Visser M, Vellas B (2009) Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people an International Academy on Nutrition and Aging (IANA) Task Force. J Nutr Health Aging 13(10):881\u2013889. https:\/\/doi.org\/10.1007\/s12603-009-0246-z","journal-title":"J Nutr Health Aging"},{"issue":"9","key":"3258_CR41","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.leukres.2013.05.013","volume":"37","author":"AE Sherman","year":"2013","unstructured":"Sherman AE, Motyckova G, Fega KR, Deangelo DJ, Abel GA, Steensma D, Wadleigh M, Stone RM, Driver JA (2013) Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. Leuk Res 37(9):998\u20131003. https:\/\/doi.org\/10.1016\/j.leukres.2013.05.013","journal-title":"Leuk Res"},{"key":"3258_CR42","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/gerona\/glp186","volume":"65","author":"RE Hubbard","year":"2010","unstructured":"Hubbard RE, Lang IA, Llewellyn DJ, Rockwood K (2010) Frailty, body mass index, and abdominal obesity in older people. J Gerontol A Biol Sci Med Sci 65:377\u2013381","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"4","key":"3258_CR43","doi-asserted-by":"publisher","first-page":"M221","DOI":"10.1093\/gerona\/55.4.M221","volume":"55","author":"JM Guralnik","year":"2000","unstructured":"Guralnik JM, Ferrucci L, Pieper CF, Leveille SG, Markides KS, Ostir GV, Studenski S, Berkman LF, Wallace RB (2000) Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci 55(4):M221\u2013M231. https:\/\/doi.org\/10.1093\/gerona\/55.4.M221","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"1","key":"3258_CR44","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40520-016-0715-2","volume":"29","author":"F Landi","year":"2017","unstructured":"Landi F, Cesari M, Calvani R, Cherubini A, Di Bari M, Bejuit R, Mshid J, Andrieu S, Sinclair AJ, Sieber CC, Vellas B, Topinkova E, Strandberg T, Rodriguez-Manas L, Lattanzio F, Pahor M, Roubenoff R, Cruz-Jentoft AJ, Bernabei R, Marzetti E, Consortium S (2017) The \"Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies\" (SPRINTT) randomized controlled trial: design and methods. Aging Clin Exp Res 29(1):89\u2013100. https:\/\/doi.org\/10.1007\/s40520-016-0715-2","journal-title":"Aging Clin Exp Res"},{"issue":"6","key":"3258_CR45","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s40265-014-0207-7","volume":"74","author":"G Gugliotta","year":"2014","unstructured":"Gugliotta G, Castagnetti F, Apolinari M, Pirondi S, Cavo M, Baccarani M, Rosti G (2014) First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies. Drugs 74(6):627\u2013643. https:\/\/doi.org\/10.1007\/s40265-014-0207-7","journal-title":"Drugs"},{"key":"3258_CR46","doi-asserted-by":"publisher","first-page":"e2014037","DOI":"10.4084\/mjhid.2014.037","volume":"6","author":"L Balducci","year":"2014","unstructured":"Balducci L, Dolan D (2014) Chronic myelogenous leukemia (CML) in the elderly. Mediterr J Hematol Infect Dis 6:e2014037","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"6","key":"3258_CR47","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/cncr.11629","volume":"98","author":"J Cortes","year":"2003","unstructured":"Cortes J, Talpaz M, O'Brien S, Giles F, Beth Rios M, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Kantarjian H (2003) Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 98(6):1105\u20131113. https:\/\/doi.org\/10.1002\/cncr.11629","journal-title":"Cancer"},{"key":"3258_CR48","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.leukres.2005.03.001","volume":"29","author":"R Latagliata","year":"2005","unstructured":"Latagliata R, Breccia M, Carmosino I, Sarlo C, Montefusco E, Mancini M, Chistolini A, De Cuia R, Russo E, Salvatore GM, Biondo F, Spadea A, Mandelli F, Alimena G, Natalino F (2005) Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment. Leukemia Res 29:287\u2013291","journal-title":"Leukemia Res"},{"issue":"1","key":"3258_CR49","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3324\/haematol.10239","volume":"92","author":"G Rosti","year":"2007","unstructured":"Rosti G, Iacobucci I, Bassi S, Castagnetti F, Amabile M, Cilloni D, Poerio A, Soverini S, Palandri F, Rege Cambrin G, Iuliano F, Alimena G, Latagliata R, Testoni N, Pane F, Saglio G, Baccarani M, Martinelli G (2007) Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. Haematologica 92(1):101\u2013105. https:\/\/doi.org\/10.3324\/haematol.10239","journal-title":"Haematologica"},{"issue":"1","key":"3258_CR50","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/annonc\/mdu490","volume":"26","author":"F Castagnetti","year":"2015","unstructured":"Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L, Abruzzese E, Rossi G, Iurlo A, Martino B, Pregno P, Stagno F, Cuneo A, Bonifacio M, Gobbi M, Russo D, Gozzini A, Tiribelli M, de Vivo A, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G (2015) Differences among young adults, adults and elderly chronic myeloid leukemia patients. Annals of oncology : official journal of the European Society for Medical Oncology 26(1):185\u2013192. https:\/\/doi.org\/10.1093\/annonc\/mdu490","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology"},{"issue":"1","key":"3258_CR51","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","volume":"126","author":"S Saussele","year":"2015","unstructured":"Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, Hanfstein B, Fabarius A, Kraemer D, Berdel WE, Bentz M, Staib P, de Wit M, Wernli M, Zettl F, Hebart HF, Hahn M, Heymanns J, Schmidt-Wolf I, Schmitz N, Eckart MJ, Gassmann W, Bartholomaus A, Pezzutto A, Leibundgut EO, Heim D, Krause SW, Burchert A, Hofmann WK, Hasford J, Hochhaus A, Pfirrmann M, Muller MC (2015) Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood 126(1):42\u201349. https:\/\/doi.org\/10.1182\/blood-2015-01-617993","journal-title":"Blood"},{"issue":"48","key":"3258_CR52","doi-asserted-by":"publisher","first-page":"80083","DOI":"10.18632\/oncotarget.11657","volume":"7","author":"A Iurlo","year":"2016","unstructured":"Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia M, Abruzzese E, Cattaneo D, Fava C, Ferrero D, Gozzini A, Bonifacio M, Tiribelli M, Pregno P, Stagno F, Vigneri P, Annunziata M, Cavazzini F, Binotto G, Mansueto G, Russo S, Falzetti F, Montefusco E, Gugliotta G, Storti S, D'Addosio AM, Scaffidi L, Cortesi L, Cedrone M, Rossi AR, Avanzini P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sora F, Rege-Cambrin G, Sica S, Luciano L, Galimberti S, Orlandi EM, Bocchia M, Tettamanti M, Alimena G, Saglio G, Rosti G, Mannucci PM, Cortelezzi A (2016) Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. Oncotarget 7(48):80083\u201380090. https:\/\/doi.org\/10.18632\/oncotarget.11657","journal-title":"Oncotarget"},{"issue":"12","key":"3258_CR53","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/ajh.23560","volume":"88","author":"L Falchi","year":"2013","unstructured":"Falchi L, Kantarjian HM, Wang X, Verma D, Quintas-Cardama A, O\u2019Brien S, Jabbour EJ, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE (2013) Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 88(12):1024\u20131029. https:\/\/doi.org\/10.1002\/ajh.23560","journal-title":"Am J Hematol"},{"issue":"1","key":"3258_CR54","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/leu.2015.270","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Rosti G, Cross NC, Steegmann JL, le Coutre P, Ossenkoppele G, Petrov L, Masszi T, Hellmann A, Griskevicius L, Wiktor-Jedrzejczak W, Rea D, Coriu D, Brummendorf TH, Porkka K, Saglio G, Gastl G, Muller MC, Schuld P, Di Matteo P, Pellegrino A, Dezzani L, Mahon FX, Baccarani M, Giles FJ (2016) Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia 30(1):57\u201364. https:\/\/doi.org\/10.1038\/leu.2015.270","journal-title":"Leukemia"},{"issue":"5","key":"3258_CR55","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM (2016) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30(5):1044\u20131054. https:\/\/doi.org\/10.1038\/leu.2016.5","journal-title":"Leukemia"},{"issue":"24","key":"3258_CR56","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362(24):2251\u20132259. https:\/\/doi.org\/10.1056\/NEJMoa0912614","journal-title":"N Engl J Med"},{"issue":"7","key":"3258_CR57","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/leu.2017.63","volume":"31","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gomez Casares MT, Hellmann A, Stentoft J, Conneally E, Garcia-Gutierrez V, Gattermann N, Wiktor-Jedrzejczak W, le Coutre PD, Martino B, Saussele S, Menssen HD, Deng W, Krunic N, Bedoucha V, Saglio G (2017) Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENEST freedom study. Leukemia 31(7):1525\u20131531. https:\/\/doi.org\/10.1038\/leu.2017.63","journal-title":"Leukemia"},{"key":"3258_CR58","unstructured":"Ross D, Masszi T, Gomez Casares MT, Hellmann A, Stentoft J, Conneally E, Garcia-Gutierrez V, Gattermann N, le Coutre P, Martino B, Saussele S, Giles F, Radich J, Saglio G, Gopalakrishna P, Deng W, Krunic N, Bedoucha V, Hochhaus A (2017) Durable treatment-free remission (TFR) following frontline nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTFREESOM 96-WK update. Paper presented at the European Hematology Association Congress, Madrid, Spain, 22\u201325 June"},{"issue":"13","key":"3258_CR59","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895\u20132901. https:\/\/doi.org\/10.1182\/blood-2008-07-170449","journal-title":"Blood"},{"issue":"4","key":"3258_CR60","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A (2011) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29(4):392\u2013397. https:\/\/doi.org\/10.1200\/JCO.2010.32.2446","journal-title":"J Clin Oncol"},{"issue":"9","key":"3258_CR61","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, Guglielmelli P, Pungolino E, Caramella M, Maffioli M, Pascutto C, Lazzarino M, Cazzola M, Tefferi A (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115(9):1703\u20131708. https:\/\/doi.org\/10.1182\/blood-2009-09-245837","journal-title":"Blood"},{"issue":"9","key":"3258_CR62","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787\u2013798. https:\/\/doi.org\/10.1056\/NEJMoa1110556","journal-title":"N Engl J Med"},{"issue":"9","key":"3258_CR63","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557","journal-title":"N Engl J Med"},{"key":"3258_CR64","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood.V128.22.3107.3107","volume":"128","author":"L Foltz","year":"2016","unstructured":"Foltz L, Palumbo A, Martino B, Palandri F, Al-Ali HK, Liberati AM, le Coutre P, Vannucchi AM, Garcia-Hernandez C, Tavares R, Griesshammer M, Gupta V, Raanani P, Giraldo P, Bouard C, Roncho JP, Khanna S, Zaritskey A (2016) Safety and efficacy of ruxolitinib for the final enrollment of JUMP: an open-label, multicenter, single-arm, expanded-access study in patients with myelofibrosis (n=2233). Blood 128:3107","journal-title":"Blood"},{"issue":"25","key":"3258_CR65","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","volume":"122","author":"F Cervantes","year":"2013","unstructured":"Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Passamonti F, Barbui T, Barosi G, Harrison CN, Knoops L, Gisslinger H, investigators C-I (2013) Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 122(25):4047\u20134053. https:\/\/doi.org\/10.1182\/blood-2013-02-485888","journal-title":"Blood"},{"issue":"4","key":"3258_CR66","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/bjh.12274","volume":"161","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM (2013) The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol 161(4):508\u2013516. https:\/\/doi.org\/10.1111\/bjh.12274","journal-title":"Br J Haematol"},{"key":"3258_CR67","doi-asserted-by":"crossref","unstructured":"Latagliata R, Di Veroli A, Palumbo GA, Bonifacio M, Andriani A, Polverelli N, Trawinska M, Tiribelli M, Anaclerico B, Benevolo G, Petriccione L, Martino B, Centra A, D\u2019Adda M, Crugnola M, Cavazzini F, Bergamaschi M, Tieghi A, Ibatici A, Bosi C, Perricone M, Montanaro M, Cavo M, Breccia M, Vianelli N, Palandri F (2016) Efficacy and safety of ruxolitinib in elderly patients (> 75 years) with myelofibrosis. Paper presented at the American Society of Hematology 58th Annual Meeting & Exposition, San Diego, California","DOI":"10.1182\/blood.V128.22.4251.4251"},{"key":"3258_CR68","unstructured":"Raanani P, Gupta V, Sadjadian P, Al-Ali HK, Giraldo P, Guglielmelli P, Foltz L, Tavares R, Zaritskey A, Bouard C, Roncho JP, Tiwari R, Martino B (2017) Safety and efficacy of ruxolitinib (RUX) in elderly patients (\u2265 75 years) with myelofibrosis (MF): an analysis from the phase 3b, expanded access JUMP study paper presented at the European Hematology Association Congress, Madrid, Spain, 22\u201325 June"},{"key":"3258_CR69","unstructured":"Palandri F, Benevolo G, Palumbo A, Bonifacio M, Di Veroli A, Polverelli N, Andriani A, Tieghi A, Tiribelli M, Binotto G, Martino B, Petriccione L, D\u2019Adda M, Crugnola M, Cavazzini F, Bergamaschi M, Isidori A, Trawinska M, Ibatici A, Bosi C, Sgherza N, Montanaro M, Breccia M, Sabattini E, Catani L, Vitolo U, Merli F, Aversa F, Vallisa D, Russo D, Semenzato P, Visani G, Fanin R, Cuneo A, Cavo M, Vianelli N, Latagliata R (2017) Efficacy and safety of ruxolitinib in elderly patients with myelofibrosis: a multicenter survey. Paper presented at the Italian Society of Haematology (SIE) conference, Rome, Italy, 15\u201318 October"},{"key":"3258_CR70","unstructured":"Breccia M, Tiribelli M, Bonifacio M, Palumbo A, Tieghi A, Polverelli N, Bergamaschi M, Cavazzini F, Isidori A, Binotto G, Cimino G, D\u2019Adda M, Crugnola M, Bosi C, Sgherza N, Spinsanti M, Molica M, Fama A, Cerqui E, Lazzaro A, Scaffidi L, Colafigli G, Latagliata R, Fanin R, Russo D, Aversa F, Cuneo A, Cavo M, Vianelli N, Foa P, Palandri F (2017) Comorbidities and body mass index impact on survival in patients with myelofibrosis treated with ruxolitinib. Paper presented at the Italian Society of Haematology (SIE) conference, Rome, Italy, 15\u201318 October"},{"key":"3258_CR71","unstructured":"Polverelli N, Binotto G, Palumbo A, Bonifacio M, Breccia M, Martino B, D\u2019Adda M, Catani L, Sabattini E, Abruzzese E, Tiribelli M, Bergamaschi M, Sgherza N, Tieghi A, Benevolo G, Cavazzini F, Isidori A, Ibatici A, Heidel F, Crugnola M, Bosi C, Latagliata R, Russo D, Cavo M, Vianelli N, Palandri F (2017) Epidemiology, outcome and risk factors for infectious complications in MF patients receiving ruxolitinib. A multicenter study on 466 patients. Paper presented at the Italian Society of Haematology (SIE) conference, Rome, Italy, 15\u201318 October"},{"issue":"5","key":"3258_CR72","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"issue":"3","key":"3258_CR73","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3324\/haematol.2010.033506","volume":"96","author":"MG Della Porta","year":"2011","unstructured":"Della Porta MG, Malcovati L, Strupp C, Ambaglio I, Kuendgen A, Zipperer E, Travaglino E, Invernizzi R, Pascutto C, Lazzarino M, Germing U, Cazzola M (2011) Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 96(3):441\u2013449. https:\/\/doi.org\/10.3324\/haematol.2010.033506","journal-title":"Haematologica"},{"issue":"2","key":"3258_CR74","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/j.1532-5415.1995.tb06377.x","volume":"43","author":"PA Parmalee","year":"1995","unstructured":"Parmalee PA, Thuras PD, Katz IR, Lawton MP (1995) Validation of the cumulative illness rating scale in a geriatric residential population. J Am Geriatr Soc 43(2):130\u2013137. https:\/\/doi.org\/10.1111\/j.1532-5415.1995.tb06377.x","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"3258_CR75","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","volume":"118","author":"R Scherber","year":"2011","unstructured":"Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Harrison CN, Radia D, Mesa RA (2011) The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 118(2):401\u2013408. https:\/\/doi.org\/10.1182\/blood-2011-01-328955","journal-title":"Blood"},{"issue":"33","key":"3258_CR76","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","volume":"30","author":"RM Emanuel","year":"2012","unstructured":"Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernandez-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA (2012) Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 30(33):4098\u20134103. https:\/\/doi.org\/10.1200\/JCO.2012.42.3863","journal-title":"J Clin Oncol"},{"issue":"3","key":"3258_CR77","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s11136-013-0523-5","volume":"23","author":"F Efficace","year":"2014","unstructured":"Efficace F, Baccarani M, Breccia M, Saussele S, Abel G, Caocci G, Guilhot F, Cocks K, Naeem A, Sprangers M, Oerlemans S, Chie W, Castagnetti F, Bombaci F, Sharf G, Cardoni A, Noens L, Pallua S, Salvucci M, Nicolatou-Galitis O, Rosti G, Mandelli F (2014) International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res 23(3):825\u2013836. https:\/\/doi.org\/10.1007\/s11136-013-0523-5","journal-title":"Qual Life Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3258-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3258-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3258-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T16:49:01Z","timestamp":1603903741000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3258-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,22]]},"references-count":77,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["3258"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3258-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,22]]},"assertion":[{"value":"10 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M. Breccia is a consultant and received honoraria from Novartis, BMS, Pfizer, Incyte, and Celgene.F. Palandri received honoraria from Novartis.L. Luciano received honoraria from Novartis, BMS, Pfizer, and Incyte.G Benevolo received honoraria from Novartis and Janssen-Cilag.M. Bonifacio received research funding from Novartis and consultancy fees from Bristol-Myers Squibb, Pfizer, and Incyte.F. Castagnetti is a consultant for and has received honoraria from Novartis, Bristol-Myers Squibb, Pfizer, and Incyte.G.A. Palumbo is a consultant for Novartis, Italy.A. Iurlo is a consultant for and received honoraria from Novartis, Bristol-Myers Squibb, Incyte, and Pfizer.G. Caocci and F. Landi have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}